Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Thoracic Malignancies Non-Small Cell Lung Cancer Small Cell Lung Cancer Mesothelioma Thoracic Malignancies Best of ASCO 2024 Muhammad Furqan, MBBS Professor, Dept. Internal Medicine University of Iowa Health Care August 24, 2024 Disclosures: Thoracic Malignancies Best of ASCO 2024 Institutional research funding: AbbVie, Amgen, Aprea, Astellas, AstraZeneca, …
PowerPoint Presentation Proto-oncogene HRAS transcript level predicts overall survival in locally advanced colorectal cancer Donghyun Kim, MD PhD Hematology and medical oncology fellow University of Iowa“I have no conflict of interest to declare” HRAS as a prognostic biomarker in locally advanced colorectal cancer Hanahan D, Weinberg RA. Hallmarks of cancer: the …
PowerPoint Presentation NAOMI FEI MD, MS 8/24/24 Upper GI Malignancies 2Carver College of Medicine Disclosure • I have no relevant financial relationships with ineligible companies to disclose. 3Carver College of Medicine Outline • Esophageal/Gastric Cancer • ESOPEC • ARMANI • Pancreatic Cancer • RTOG 0848 • GIANT • Cholangiocarcinoma • …
PowerPoint Presentation Metastatic Colon Cancer Dulabh K. Monga MD Associate Professor of Medicine Drexel University School of Medicine Allegheny Health Network Cancer Institute Pittsburgh Disclosures Speakers Bureau: Bristol Myers Squibb Astra Zeneca Advisory Board: Astra Zeneca Key Studies in Metastatic Colorectal Cancer ASCO 2024 ➢ Checkmate …
GI Oncology Update: Adjuvant & Metastatic Colorectal Cancer Insert->Header and Footer->Type Customizable Name Best of ASCO 2024 Updates in Neoadjuvant and Adjuvant Treatment of Colon & Rectal Cancers, Anal Cancers Saima Sharif, MD MS August 24, 2024 Disclosure • I have permission to use slides from Annual Meeting 2024 • Saima Sharif, MD MS reports: • Grant/research …
Example of the Presentation Title Slide Leukemias Notable abstracts in leukemia and MDS Grerk Sutamtewagul, MD Clinical Associate Professor, University of Iowa August 24, 2024 Best of ASCO 2024 - Iowa City 2Carver College of Medicine Disclosure • I received research fundings from Arog Pharmaceuticals, Syros, Novartis, Gilead, Bristol Myers, Kura Oncology, …
Effective partnerships between dermatologists and oncologists are an essential component of care coordination for patients with advanced non-melanoma skin cancers. This interprofessional collaboration can be more challenging in the community setting, where fewer resources are available in comparison to large academic medical centers.
Adjuvant Osimertinib for Resected Stage IB-IIIA Non-Small Cell Lung Cancer Trends in Hematopoietic Cell Transplantation in Acute Myeloid Leukemia from 2004-2020 Aditya Ravindra MD Hematology & Medical Oncology Fellow Mentor: Prajwal Dhakal MD Iowa Oncology Society 2024 Best of ASCO Financial Disclosures This work was supported by clinical research funds from the Holden …
PowerPoint Presentation Vincent Wagner, MD Gynecologic Oncology Best of ASCO I have no relevant financial relationships or conflicts of interests to disclose Disclosure G Y N E C O L O G I C O N C O L O G Y – B E S T O F A S C O CERVIX CANCER G Y N E C O L O G I C O N C O L O G Y – B E S T O F A S C O RTOG 0724/GOG-0724 G Y N E …
PowerPoint Presentation August, 24, 2024 SARCOMA Disclosures • Sponsored Research- Cogent Biosciences, Inc. • Sponsored Research- Ascentage Pharma Group, Inc. • Advisory Board: Deciphera Pharmaceuticals • “A riddle wrapped in a mystery inside an enigma” • Very challenging to study and understand • Derived from mesenchymal stem cells (behave differently …
PHASE Ib PILOT STUDY OF ITACITINIB WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA Kadia T, Jain A, Ravandi F, Borthakur G, Jabbour E, Montalban-Bravo G, Adewale L, Pierce S, Lacke C, Brandt M, Short N, Jain N, Burger J, Ferrajoli A, Wierda W, Kantarjian H Presenter:- Akhil Jain, MD Fellow, Holden Comprehensive Cancer Center Disclosure- none Background …
Updates on Neoadjuvant Immune therapy in Melanoma Neoadjuvant Immune Therapy in Melanoma Updates from ASCO 2024 Asad Javed, MBBS Holden Comprehensive Cancer Center University of Iowa Disclosures • Immunocore: Member, steering committee Why consider a Neoadjuvant Approach? • Resection of tumor bulk removes the immunologic targets as well as the …
PowerPoint Presentation August 24, 2024 Multiple Myeloma ASCO 2024 Highlights T I T L E Disclosures • No financial disclosures. Holden Comprehensive Cancer Center Acknowledgements • Thank you to the abstract presenters for use of their slides: –Dr. Facon (Abstract # 7500) –Dr. Trudel (Abstract # LBA105) –Dr. Touzeau (Abstract # 7507) –Dr. Leleu …
Maximizing the Therapeutic Potential of PRRT for Neuroendocrine Tumors Maximizing the Therapeutic Potential of PRRT for Neuroendocrine Tumors Udhayvir Singh Grewal, MD University of Iowa Hospitals and Clinics, Iowa City, IA WHO Classification of NENs Therapeutic paradigm for NETs Chauhan et al. 2022 CABINET ESMO 2023 Peptide Receptor …
Example of the Presentation Title Slide Best of ASCO 2024 Lymphoma Abstracts PRESENTED BY: NANMENG YU, MD, PHD, UNIVERSITY OF IOWA August 24, 2024 2Carver College of Medicine Disclosure • I have no relevant financial relationships with ineligible companies to disclose. 3Carver College of Medicine Classical Hodgkin Lymphoma (cHL) • Bimodal presentation • …
August 24, 2024
In conjunction with: Be part of an exclusive gathering at the IOS 2024 Best of ASCO® this upcoming August. This officially licensed 'Best of' event offers a thorough analysis of groundbreaking research and clinical data from the ASCO® 2024 Annual Meeting. Enhance your clinical strategies by learning from the "Best of" abstracts in a …
August 24, 2024
Join us for a complimentary evening of cocktails, hors d'oeuvres and networking at our Meet & Greet Reception, hosted by the Nevada Oncology Society (NOS). This event will take place on Friday, August 23rd, after day one at the Nevada Cancer Control Summit. The reception presents a fantastic opportunity to connect with local oncology professionals and attendees. You don't have to be a NOS member …
August 23, 2024
You’re invited to participate in the Targeted Oncology™ Community Case Forum™ on Friday, August 23 at Graduate Iowa City. HRA® offers compensation of $750 to medical oncologists/hematologists for their consultative insights. With prior approval from our registration team, a small number of fellows and advanced practice providers may be eligible to attend. After arriving, you’ll spend some time networking …
August 23, 2024
Selecting and Sequencing Therapy for Patients with DLBCL in an Era of Expanding Options The Community Oncology Connections™ Program will feature didactic presentations coupled with cases and discussion. This provides an ideal format to exchange ideas and viewpoints, as well as to hear experts apply the latest practice-changing clinical trial data, evidence-based testing, and therapeutic strategies …
Equitable access to supportive care services is crucial for patients with cancer to ensure that their needs are met and they can achieve the best treatment outcomes possible.